Stock Analiz

Editas Medicine, Inc. EDIT

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2016 · data as of November 13, 2026

$2.17Market cap $335M
Open the interactive analysis →

Editas Medicine, Inc. (EDIT) is a healthcare company listed in the US with a market value of about $335M. In the twelve months to September 30, 2026 it had revenue of $50M and net income of -$72M, a net margin of -145.0%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -15% a year, a 5-year average ROIC of -63%.

About Editas Medicine

Editas Medicine is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2016. Revenue went from $6M in 2016 to $41M in 2025, growth of about 23.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 29% over three years (dilution for shareholders). It spends 222% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth4/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S6.7
P/B4.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-33.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)25.4%
Revenue growth (5 yrs, per year)-14.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-639.4%
ROIC (5-yr avg.)-62.8%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$50M$41M$32M$78M$20M$26M$91M$21M$32M$14M$6M
Net income-$72M-$160M-$237M-$153M-$220M-$193M-$116M-$134M-$110M-$120M-$97M
Free cash flow-$110M-$166M-$219M-$137M-$181M-$172M-$187M-$47M-$50M-$11M-$54M
EPS (diluted)$-0.54$-1.80$-2.88$-2.02$-3.21$-2.85$-1.98$-2.68$-2.33$-2.98$-3.02
Net margin-145.0%-395.0%-733.7%-196.1%-1118.3%-753.6%-127.8%-651.4%-344.3%-876.5%-1605.5%
ROIC—-121.5%-87.5%-34.7%-44.1%-26.3%-25.4%-38.2%-35.1%-44.0%-53.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 10 analysts is $6.10, 181% above the current price; targets range from $1.00 to $15.00; the consensus rating is “Buy”; expected EPS is $-0.75 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Editas Medicine pay a dividend?

Not currently.

Is Editas Medicine a good stock to buy?

We do not give buy or sell advice. Editas Medicine scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.